Apogee Therapeutics, Inc.
NGM: APGELive Quote
📈 ZcoreAI Score
Our AI model analyzes Apogee Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get APGE Z-Score →About Apogee Therapeutics, Inc.
Healthcare
Biotechnology
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial. It also develops APG279 which is in phase 1 clinical trial for the treatment of atopic dermatitis; APG273 which is in phase 1 clinical trial for the treatment of asthma and chronic obstructive pulmonary disease; and APG808, an SQ extended half-life mAb targeting IL-4Ra for the treatment of Type 2 allergic diseases. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.
📊 Fundamental Analysis
Apogee Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -31.6%, which indicates that capital utilization is currently under pressure.
At a current price of $86.27, APGE currently trades near the top of its 52-week range (96%) (Range: $31.21 - $88.35).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$6.44B
Trailing P/E
--
Forward P/E
-15.83
Beta (5Y)
1.02
52W High
$88.35
52W Low
$31.21
Avg Volume
1.05M
Day High
Day Low